The Promise of Lenacapavir: Breakthrough HIV Injection Faces Global Access Hurdles

A health official holds lenacapavir, a long‑acting HIV prevention treatment, in Epworth outside the capital Harare, Zimbabwe, February 19, 2026. A medicine injected just twice a year could transform the fight against HIV, following a 2024 clinical trial involving more than 2,000 young women in South Africa and Uganda where no participants who received lenacapavir contracted the virus.

Developed by United States pharmaceutical company Gilead Sciences, the injectable drug has been hailed as a monumental advancement. Carlota Baptista da Silva, global HIV lead at Doctors Without Borders (known by its French initials, MSF), told Al Jazeera that it is the most innovative tool in the HIV arena for a decade, serving as the closest option yet to a vaccine. The World Health Organization has endorsed the long-acting injectable as an additional form of pre-exposure prophylaxis (PrEP).

However, the introduction of lenacapavir coincides with a difficult period for international funding, which fell 18 percent in 2025 to $7.3bn, according to the United Nations programme on HIV/AIDS (UNAIDS). As prevention programmes face severe budget constraints, questions surrounding affordability and distribution have intensified.

While lenacapavir costs approximately $28,000 per person annually in the United States, generic alternatives are projected to cost about $40 a year. Gilead has licensed six manufacturers to produce generic versions, though large-scale rollouts are not anticipated until 2027. Meanwhile, at least 26 middle-income countries—including Brazil, Mexico, Argentina, and Peru—are excluded from the generics agreement, prompting concerns from health advocates.

Gilead has established a separate agreement with the Pan American Health Organization to create access pathways for 14 Latin American and Caribbean nations. Yet, organizations like MSF argue these measures leave countries dependent on Gilead rather than able to access cheaper generics automatically. Furthermore, MSF reports it has been unable to purchase lenacapavir directly from Gilead for its humanitarian operations.

In response, international health advocates suggest that governments could utilize World Trade Organization rules, such as compulsory licensing, to bypass patent barriers and secure affordable generic versions. As production scales up toward Gilead's goal of supplying three million people through 2028, the ultimate test remains whether scientific innovation will be distributed based on human need rather than geographic or economic status.